Catalyst

Slingshot members are tracking this event:

US FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY

100%

Additional Information

http://news.bms.com/...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda Approval, Daklinza, Daclatasvir, Genotype 1, Genotype 3, Chronic Hepatits C